La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Regulus Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Regulus Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$0.54
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di RGLS siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di RGLS siano aumentati.

Rendimento dei dividendi rispetto al mercato

Regulus Therapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di RGLS rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (RGLS)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.4%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (RGLS)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di RGLS rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di RGLS rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di RGLS per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché RGLS non ha segnalato alcun pagamento.

Regulus Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

New minor risk - Profitability

New minor risk - Market cap size

Price target increased by 49% to US$11.00

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus surges 15% after Phase 1 data for kidney disease candidate

Price target increased to US$20.00

Regulus Therapeutics GAAP loss per share narrows

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Price target increased to US$20.00

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$1.50

Full year 2021 earnings: EPS misses analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Consensus forecasts updated

The Read On Regulus Therapeutics

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

Analysts update estimates

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

New 90-day high: US$1.94

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: US$1.55

New 90-day high: US$1.21

Regulus Therapeutics announces closing of $19.4M private placement

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding

New 90-day high: US$0.66

Revenue beats expectations, earnings disappoint

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Analysts lower revenue estimates to US$3.77m

New 90-day low - US$0.53